Bailey, Donald B. Jr
Gehtland, Lisa M.
Lewis, Megan A.
Peay, Holly
Raspa, Melissa
Shone, Scott M.
Taylor, Jennifer L.
Wheeler, Anne C.
Cotten, Michael
King, Nancy M. P.
Powell, Cynthia M.
Biesecker, Barbara
Bishop, Christine E.
Boyea, Beth Lincoln
Duparc, Martin
Harper, Blake A.
Kemper, Alex R.
Lee, Stacey N.
Moultrie, Rebecca
Okoniewski, Katherine C.
Paquin, Ryan S.
Pettit, Denise
Porter, Katherine Ackerman
Zimmerman, Scott J.
Funding for this research was provided by:
National Center for Advancing Translational Sciences (U01TR001792, UL1TR001111)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (HHSN27500003)
Asuragen (Not Applicable)
John Merck Fund (Not Applicable)
Cure SMA (Not Applicable)
Article History
Received: 4 April 2019
Accepted: 30 June 2019
First Online: 17 July 2019
Ethics approval and consent to participate
: The University of North Carolina at Chapel Hill (UNC-CH) serves as the central Institutional Review Board for the Early Check study. The project (#18–0009) was approved by the UNC-CH Biomedical Institutional Review Board on June 20, 2018 following full board review. The UNC-CH IRB classified the study as “no greater than minimal risk,” and approved the use of electronic consent.
: Not applicable.
: The individual authors of this paper declare no competing interests. Early Check is supported in part by contributed reagents and equipment from Asuragen, but none of the authors has a personal or financial relationship with Asuragen.